Sign in
Taking peoplePhase 3

Bevacizumab added to steroids for brain radionecrosis after radiotherapy for brain metastases

Tests bevacizumab versus placebo alongside steroids in adults with symptomatic brain radionecrosis.

Key facts

Who runs it
Institut Cancerologie de l'Ouest
Where
France22 sites in 1 countryChoose a country to see its sites
Registry title
Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases
Status
Recruiting
Phase
Phase 3
People taking part
84 people, planned
Started
29 Apr 2025
Expected to end
Aug 2030
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Bevacizumab
  • Placebo
  • Prednisolone
Record updated
17 August 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with brain radionecrosis (brain tissue damage from radiotherapy) after radiotherapy for brain metastases. Their symptoms must persist or worsen despite steroid treatment.

Age
18 years and older
Sex
All sexes
Disease stage
Radionecrosis with symptoms, shown on MRI combined with nuclear medicine imaging (18FDG-PET or 18F-FDOPA). Symptoms continue despite at least 2 weeks of 1 mg/kg/d prednisolone or equivalent, or return when steroids are lowered below 0.5 mg/kg/d. ECOG performance status score ≤ 3. Life expectancy of at least 3 months (DS-GPA score 0.5 or greater).
Earlier treatment
Last brain radiotherapy (photons or proton therapy) for brain metastases at least 3 months ago. Never had Bevacizumab for radionecrosis. No bevacizumab in the 3 months before joining.

Main reasons for not taking part

  • Active bleeding or high risk of bleeding
  • Brain metastases that are growing, or new brain metastases found at the start
  • Serious heart or blood vessel disease, or uncontrolled high blood pressure
  • Major surgery or serious injury in the last 28 days
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 32 criteriaShow less

Who can take part

  • Patient with a diagnosis of radionecrosis based on a clinical onset of symptoms and radiological findings of RN following radiotherapy, with or without pathological confirmation:; MRI evidence to support the diagnosis of RN (transient increase in irradiated lesion volume -FLAIR hypersignal and/or enhanced portion- without rCBV increase) COMBINED with nuclear medicine imaging:; biphasic 18FDG-PET-TDM/MRI according to Horky or 18F-FDOPA with stage 0-1 according to Lizarraga
  • Symptoms are persistent or worsening despite administration of corticosteroids: at least 1 mg/kg/d of prednisolone or equivalent:; Corticoresistant: neurological symptoms despite administration of at least 2 weeks of 1 mg/kg/d prednisolone or equivalent; Corticodependant: worsening of neurological signs or symptoms after an initial improvement when weaning off steroids at a dose < 0.5 mg/kg/d prednisolone or equivalent
  • Patients must have received the last cranial irradiation with photons or proton therapy for brain metastases ≥ 3 months with one or more sequences
  • Age≥18-year-old
  • ECOG performance status score ≤ 3
  • Life expectancy of at least 3 months assessed by graded prognostic score (DS-GPA) score 0.5 or greater
  • Patient who has never received Bevacizumab for the indication of radionecrosis
  • Adequate organ function:; Bone marrow function
  • Absolute Neutrophil Count (ANC) ≥ 1,500/mm3 Platelet Count ≥ 100,000/mm3, Haemoglobin ≥ 10 g/dL (allowing transfusion or other intervention to achieve this minimum haemoglobin) Coagulation
  • International normalized ratio (INR) or prothrombin time < 1.5 × ULN Renal function
  • No proteinuria with urine dipstick for proteinuria > 2+
  • Serum creatinine ≤1.5 x ULN or creatinine clearance ≥50 mL/min (measured or calculated using the CDK-EPI formula) Hepatic Function
  • Total bilirubin ≤1.5 x the upper limit of normal (ULN)
  • Alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤3 x ULN; Women of childbearing potential must use effective contraceptive measures during the treatment and for 6 months following its cessation; Signed informed consent; Patient affiliated to a social security scheme

Who cannot take part

  • Evidence of active bleeding or a pathological condition at high risk of bleeding: CNS hemorrhage, bleeding diathesis or coagulopathy, hemoptysis (>2.5ml of bright red blood per episode), evidence of history of bowel obstruction, abdominal fistula, or gastrointestinal tract perforation or gastro intestinal abscess occurring less than 28 days prior study entry
  • Evidence of very high intracranial pressure that suggests brain hernia and needs emergency surgery
  • Major surgical procedure or significant traumatic injury less than 28 days prior study entry; minor surgery within 3 days prior to initiation of study treatment
  • Patients scheduled to undergo head and neck, thoracic, or abdominal radiotherapy during the study treatment
  • Prior bevacizumab ≤ 3 months before randomization
  • Patients with a contraindication to the treatment with bevacizumab according to the European SmPC
  • Prior diagnosis of Posterior Reversible Encephalopathy Syndrome (PRES) with bevacizumab
  • Clinically significant cardiovascular disease such as uncontrolled arterial hypertension (BP ≥160 mm Hg or diastolic BP ≥100 mm Hg despite maximal medical therapy), cerebrovascular event, myocardial infarction, cardiac arrhythmias, unstable angina, or congestive heart failure within the last 6 months
  • History of hypertensive crisis or hypertensive encephalopathy
  • History of severe allergic anaphylactic reactions to bevacizumab
  • Patients with a known hypersensitivity to the active substance or to any of the excipients of bevacizumab are not eligible for participation
  • Mental impairment (psychiatric illness/social situations) that may compromise the ability of the patient to give informed consent and comply with the requirements of the study
  • Hypersensitivity known to Chinese Hamster Ovary (CHO) cell products or other recombinant human or humanised antibodies
  • Grade 4 venous thromboelism and peripheral arterial thrombus
  • Progressive brain metastases
  • Patient pregnant and/or nursing
  • Patient who has forfeited his/her freedom by administrative or legal award or who is under guardianship
  • New cerebral metastasis detected during the inclusion imaging evaluation

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Brain metastases (BM) afflict a significant portion of cancer patients, ranging from 10% to 50%, leading to debilitating symptoms and diminished quality of life, thereby impacting overall survival. Treatment options typically include surgery, stereotactic radiosurgery (SRS), and whole brain radiotherapy (WBRT). SRS has emerged as the preferred focal treatment due to its efficacy, delivering ablative doses with notable overall survival benefits, especially for single BM or postoperative cases, while being less invasive than neurosurgery and capable of addressing inoperable sites and multiple lesions. Contrastingly, WBRT is now reserved for select cases with multiple BMs ineligible for SRS, owing to its lower rate of neurocognitive toxicities and high local control rates at one year.

Read full original descriptionShow less

Despite its advantages, SRS can engender late side effects, with cerebral radio necrosis (RN) being the most common, occurring in approximately 10% of patients treated. The exact pathophysiology of RN remains unclear but is thought to involve vascular injury, immune-mediated mechanisms, and direct neuronal effects, culminating in radiological changes or symptomatic manifestations necessitating treatment. Corticosteroids are the mainstay therapy, albeit with associated side effects and instances of cortico-resistance or cortico-dependence. Bevacizumab, an anti-VEGF agent, has shown promise in small studies but awaits validation in larger trials.

Consequently, a randomized phase III trial seeks to evaluate the efficacy of adding bevacizumab to standard corticosteroid therapy in patients with symptomatic RN. The trial aims to determine if this combination therapy yields superior symptomatic improvement compared to corticosteroids alone. RN will be diagnosed using multimodal imaging, and the primary objective is to assess the efficacy of bevacizumab in reducing corticosteroid usage and neurological symptoms associated with RN at three months. Secondary endpoints include toxicities, quality of life, imaging changes, and response duration. Additionally, an ancillary study will explore correlations between initial imaging parameters and treatment response, as well as changes in biological parameters with bevacizumab therapy.

The 2 groups in the trial

  • Experimental armTreatment being tested

    Experimental: bevacizumab + prednisolone The patient will receive bevacizumab 7.5 mg/kg IV given on Q3W for4 cycles or until progression of radionecrosis or unacceptable adverse event. Once the patient has started the study treatment, the dose of prednisolone will be tapered every 7 days beginning at C2D1 (at least 10 mg prednisolone or equivalent), depending on tolerance. If the patient weighs more than 100 kg, the tapering can be increased by 10 to 20 mg per week for the first 3 months. Interventions: Drug: bevacizumab Drug : prednisolone

    Treatment: Bevacizumab and Prednisolone

  • Placebo armPlacebo, for comparison

    Placebo arm: placebo + prednisolone The patient will receive placebo 0.9% NaCl volume equal to bevacizumab volume added to 100 mL bag of 0.9% NaCl delivered IV given on on Q3W for4 cycles or until progression of radionecrosis or unacceptable adverse event. Once the patient has started the study treatment, the dose of prednisolone will be tapered every 7 days beginning at C2D1 (at least 10 mg prednisolone or equivalent), depending on tolerance. If the patient weighs more than 100 kg, the tapering can be increased by 10 to 20 mg per week for the first 3 months. Interventions: Drug: placebo Drug : prednisolone

    Treatment: Placebo and Prednisolone

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases: a Multicentre Randomized, Controlled Double-blind Phase III Study, Comparing Bevacizumab Versus Placebo
Plain-language title
Bevacizumab added to steroids for brain radionecrosis after radiotherapy for brain metastasesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
17 August 2025